GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Beneish M-Score

Andros Pharmaceuticals Co (ROCO:6917) Beneish M-Score : -3.94 (As of Jun. 05, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.94 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Andros Pharmaceuticals Co's Beneish M-Score or its related term are showing as below:

ROCO:6917' s Beneish M-Score Range Over the Past 10 Years
Min: -3.94   Med: -0.27   Max: 6
Current: -3.94

During the past 5 years, the highest Beneish M-Score of Andros Pharmaceuticals Co was 6.00. The lowest was -3.94. And the median was -0.27.


Andros Pharmaceuticals Co Beneish M-Score Historical Data

The historical data trend for Andros Pharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Beneish M-Score Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - -0.27 6.00 -3.94

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Beneish M-Score Get a 7-Day Free Trial -0.27 - 6.00 - -3.94

Competitive Comparison of Andros Pharmaceuticals Co's Beneish M-Score

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Andros Pharmaceuticals Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Beneish M-Score falls into.



Andros Pharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Andros Pharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.141+0.528 * 1.4503+0.404 * 1.0582+0.892 * 0.4699+0.115 * 0.8998
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.005+4.679 * -0.040667-0.327 * 0.7298
=-3.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was NT$0.44 Mil.
Revenue was NT$0.81 Mil.
Gross Profit was NT$0.31 Mil.
Total Current Assets was NT$452.69 Mil.
Total Assets was NT$529.15 Mil.
Property, Plant and Equipment(Net PPE) was NT$28.70 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$6.20 Mil.
Selling, General, & Admin. Expense(SGA) was NT$17.16 Mil.
Total Current Liabilities was NT$31.97 Mil.
Long-Term Debt & Capital Lease Obligation was NT$22.02 Mil.
Net Income was NT$-68.16 Mil.
Gross Profit was NT$0.00 Mil.
Cash Flow from Operations was NT$-46.64 Mil.
Total Receivables was NT$6.70 Mil.
Revenue was NT$1.71 Mil.
Gross Profit was NT$0.97 Mil.
Total Current Assets was NT$268.03 Mil.
Total Assets was NT$329.60 Mil.
Property, Plant and Equipment(Net PPE) was NT$33.45 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$6.36 Mil.
Selling, General, & Admin. Expense(SGA) was NT$12.15 Mil.
Total Current Liabilities was NT$19.68 Mil.
Long-Term Debt & Capital Lease Obligation was NT$26.40 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.444 / 0.805) / (6.702 / 1.713)
=0.551553 / 3.912434
=0.141

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.966 / 1.713) / (0.313 / 0.805)
=0.563923 / 0.38882
=1.4503

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (452.687 + 28.699) / 529.146) / (1 - (268.03 + 33.454) / 329.597)
=0.090259 / 0.085295
=1.0582

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.805 / 1.713
=0.4699

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.362 / (6.362 + 33.454)) / (6.197 / (6.197 + 28.699))
=0.159785 / 0.177585
=0.8998

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17.162 / 0.805) / (12.153 / 1.713)
=21.319255 / 7.094571
=3.005

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((22.024 + 31.97) / 529.146) / ((26.403 + 19.679) / 329.597)
=0.10204 / 0.139813
=0.7298

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-68.159 - 0 - -46.64) / 529.146
=-0.040667

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Andros Pharmaceuticals Co has a M-score of -3.94 suggests that the company is unlikely to be a manipulator.


Andros Pharmaceuticals Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Andros Pharmaceuticals Co (ROCO:6917) Business Description

Traded in Other Exchanges
N/A
Address
No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines